Cleavable PEG-Conjugated Antibody for Reducing Immune Side Effects
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Immune checkpoint inhibitor antibodies for cancer treatment often cause immune-related side effects, such as anemia, colitis, and autoimmune reactions, which can be severe and require lifelong hormone supplementation or immunosuppression, reducing the quality of life and therapeutic efficacy.
Innovation Solution
Conjugating tumor environment-sensitive cleavable polyethylene glycol (PEG) to antibodies, which are specifically designed to be cleaved in the acidic tumor environment, reducing immune-related side effects while maintaining therapeutic efficacy by altering the antibody's behavior and interaction with the immune system.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immune checkpoint inhibitor antibodies are administered for cancer treatment, then therapeutic efficacy is improved, but immune-related side effects worsen
Solution Approach 1:
The patent introduces a cleavable PEG linker as an intermediary between the antibody and the tumor microenvironment. This linker acts as a mediator that remains stable in circulation but cleaves in the acidic tumor environment, releasing the antibody to exert therapeutic effects only where needed, thus reducing systemic immune-related side effects while maintaining cancer treatment efficacy
Solution Approach 2:
The patent utilizes pH parameter changes in the tumor microenvironment (acidic conditions) to trigger the cleavage of the PEG linker. By designing the linker to be sensitive to pH changes, the system achieves environment-specific activation of the antibody, allowing therapeutic action to occur only in the acidic tumor milieu rather than throughout the entire body
2Object-generated harmful factors
If PEG is conjugated to antibodies to reduce side effects, then immune-related side effects are suppressed, but therapeutic effects may be compromised
Solution Approach 1:
The patent employs a dynamic PEG conjugation system where the PEG linker is not permanently attached but can be cleaved under specific conditions. This dynamic design allows the antibody to circulate with PEG protection (reducing side effects) and then release the PEG in the tumor microenvironment to restore full therapeutic activity, thus resolving the contradiction between side effect reduction and therapeutic efficacy
Solution Approach 2:
The patent segments the antibody structure by attaching PEG to specific regions (such as the Fc portion) while leaving the antigen-binding sites (Fab regions) intact and accessible. This segmentation allows the PEG to provide protective effects without interfering with the antibody's ability to bind to tumor antigens and exert therapeutic effects
3Adaptability or versatility
If PEG conjugation is used to alter antibody behavior, then interaction with immune system is modified, but manufacturing complexity increases
Solution Approach 1:
The patent employs a disposable, single-use PEG linker that is inexpensive to synthesize and attach to antibodies. The linker is designed to be cleaved after serving its protective function during circulation, eliminating the need for complex removal or modification processes. This approach simplifies manufacturing by using a straightforward conjugation and cleavage mechanism rather than requiring complex multi-step procedures
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The conjugation of tumor environment-sensitive cleavable PEG to antibodies suppresses immune-related side effects while preserving the therapeutic effects of immune checkpoint inhibitor antibodies, reducing anemia and colitis, and enhancing cancer treatment efficacy by selectively activating in the tumor microenvironment.
Implementation Method 1
tumor environment-sensitive cleavable polyethylene glycol which is conjugated to the antibody for cancer treatment and is specifically designed to be cleaved in an acidic environment such as a tumor microenvironment
Data Source
AI summary
Disclosed is an antibody for cancer treatment conjugated with a tumor environment-sensitive cleavable polyethylene glycol, wherein the use of the antibody for cancer treatment can suppress side effects of the antibody while maintaining therapeutic effects thereof.